Racial Variation in Willingness to Trade Financial Resources for Life-Prolonging Cancer Treatment

被引:18
|
作者
Martin, Michelle Y. [1 ]
Pisu, Maria
Oster, Robert A.
Urmie, Julie M. [2 ]
Schrag, Deborah [3 ]
Huskamp, Haiden A. [4 ]
Lee, Jeannette [5 ]
Kiefe, Catarina I. [6 ]
Fouad, Mona N.
机构
[1] Univ Alabama, Dept Med, Div Prevent Med, Sch Med, Birmingham, AL 35294 USA
[2] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA
[5] Univ Arkansas, Dept Biostat, Little Rock, AR 72204 USA
[6] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA
关键词
treatment; preferences; cancer; race; financial resources; tradeoffs; CARE OUTCOMES RESEARCH; OF-LIFE; TREATMENT PREFERENCES; ETHNIC-DIFFERENCES; AFRICAN-AMERICAN; ADVANCE DIRECTIVES; WHITE PATIENTS; END; ATTITUDES; SUPPORT;
D O I
10.1002/cncr.25839
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Minority patients receive more aggressive care at the end of life, but it is unclear whether this trend is consistent with their preferences. We compared the willingness to use personal financial resources to extend life among white, black, Hispanic, and Asian cancer patients. METHODS: Patients with newly diagnosed lung or colorectal cancer participating in the Cancer Care Outcomes Research and Surveillance observational study were interviewed about myriad aspects of their care, including their willingness to expend personal financial resources to prolong life. We evaluated the association of race/ethnicity with preference for life-extending treatment controlling for clinical, sociodemographic, and psychosocial factors using logistic regression. RESULTS: Among patients (N = 4214), 80% of blacks reported a willingness to spend all resources to extend life, versus 54% of whites, 69% of Hispanics, and 72% of Asians (P<.001). In multivariate analyses, blacks were more likely to opt for expending all financial resources to extend life than whites (odds ratio, 2.41; 95% confidence interval, 1.84-3.17; P < .001). CONCLUSIONS: Black cancer patients are more willing to exhaust personal financial resources to extend life. Delivering quality cancer care requires an understanding of how these preferences impact cancer care and outcomes. Cancer 2011;117:3476-84. (C) 2011 American Cancer Society.
引用
收藏
页码:3476 / 3484
页数:9
相关论文
共 50 条
  • [41] "Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment
    Loeffeler, Sven
    Weedon-Fekjaer, Harald
    Wang-Hansen, Marte Sofie
    Sebakk, Karin
    Hamre, Hanne
    Haug, Erik S.
    Fossa, Sophie D.
    SCANDINAVIAN JOURNAL OF UROLOGY, 2015, 49 (06) : 440 - 445
  • [42] Ethical analysis of life-prolonging treatment. For protection of self-determination and protection against overtreatment
    Mehlis, K.
    Winkler, E. C.
    ONKOLOGE, 2016, 22 (11): : 844 - 851
  • [43] Life-prolonging treatment in nursing homes: how do physicians and nurses describe and justify their own practice?
    Dreyer, A.
    Forde, R.
    Nortvedt, P.
    JOURNAL OF MEDICAL ETHICS, 2010, 36 (07) : 396 - 400
  • [44] Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients
    Caffo, Orazio
    Frantellizzi, Viviana
    Monari, Fabio
    Sbrana, Andrea
    Costa, Renato Patrizio
    Pinto, Carmine
    Tucci, Marcello
    Baldari, Sergio
    Facchini, Gaetano
    Bortolus, Roberto
    Alongi, Filippo
    Alongi, Pierpaolo
    Palermo, Antonio
    Fanti, Stefano
    Biasco, Elisa
    Murabito, Alessandra
    Filice, Angelina
    Zichi, Clizia
    Pignata, Salvatore
    Borsatti, Eugenio
    Salgarello, Matteo
    Spada, Massimiliano
    Cortesi, Enrico
    Vincentis, Giuseppe De
    FUTURE ONCOLOGY, 2021, 17 (07) : 807 - 815
  • [45] Ethics consultants' recommendations for life-prolonging treatment of patients in persistent vegetative state: A follow-up study
    Fox, Ellen
    Daskal, Frona C.
    Stocking, Carol
    JOURNAL OF CLINICAL ETHICS, 2007, 18 (01): : 64 - 71
  • [46] The role of hospital nurses in shared decision-making about life-prolonging treatment: A qualitative interview study
    Bos-van den Hoek, Danique W.
    Thode, Maureen
    Jongerden, Irene P.
    Van Laarhoven, Hanneke W. M.
    Smets, Ellen M. A.
    Tange, Dorien
    Henselmans, Inge
    Pasman, H. Roeline
    JOURNAL OF ADVANCED NURSING, 2021, 77 (01) : 296 - 307
  • [47] Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
    de Joode, Karlijn
    Tol, Jolien
    Hamberg, Paul
    Cloos, Marissa
    Kastelijn, Elisabeth A.
    Borgers, Jessica S. W.
    Nuij, Veerle J. A. A.
    Klaver, Yarne
    Herder, Gerarda J. M.
    Mutsaers, Pim G. N. J.
    Dumoulin, Daphne W.
    Oomen-de Hoop, Esther
    van Diemen, Nico G. J.
    Libourel, Eduard J.
    Geraedts, Erica J.
    Bootsma, Gerben P.
    van der Leest, Cor H.
    Peerdeman, Anne L.
    Herbschleb, Karin H.
    Visser, Otto J.
    Bloemendal, Haiko J.
    van Laarhoven, Hanneke W. M.
    de Vries, Elisabeth G. E.
    Hendriks, Lizza E. L.
    Beerepoot, Laurens, V
    Westgeest, Hans M.
    van den Berkmortel, Franchette W. P. J.
    Haanen, John B. A. G.
    Dingemans, Anne-Marie C.
    van der Veldt, Astrid A. M.
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 261 - 272
  • [48] Understanding End-of-Life Preferences: Predicting Life-Prolonging Treatment Preferences Among Community-Dwelling Older Americans
    Brenner, Allison B.
    Skolarus, Lesli E.
    Perumalswami, Chithra R.
    Burke, James F.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2020, 60 (03) : 595 - +
  • [49] Effects of an ethics policy on limitations of life-prolonging treatment (EPAL) on DNR orders and transferal to palliative care settings
    Mehlis, K.
    Bierwirth, E.
    Laryionava, K.
    Mumm, F.
    Hiddemann, W.
    Heussner, P.
    Winkler, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 22 - 22
  • [50] Why I wrote my advance decision to refuse life-prolonging treatment: and why the law on sanctity of life remains problematic
    Gillon, Raanan
    JOURNAL OF MEDICAL ETHICS, 2016, 42 (06) : 376 - 382